68 results
8-K
EX-99.1
URGN
UroGen Pharma Ltd
18 Jun 24
UroGen Pharma Announces Commencement of Public Offering of Ordinary Shares and Pre-Funded Warrants
5:07pm
@tdsecurities.com; or Guggenheim Securities, LLC, Attention: Equity Syndicate Department, 330 Madison Avenue, New York, NY 10017, telephone: (212) 518-5548, email
8-K
EX-1.1
URGN
UroGen Pharma Ltd
18 Jun 24
UroGen Pharma Announces Commencement of Public Offering of Ordinary Shares and Pre-Funded Warrants
5:07pm
, the Office of Foreign Assets Control of the U.S. Department of the Treasury (“OFAC”), or the U.S. Department of State and including, without … be required for the conduct of the studies by the Israeli Ministry of Health, the Food and Drug Administration of the U.S. Department of Health and Human
8-K
EX-99.2
URGN
UroGen Pharma Ltd
18 Jun 24
UroGen Pharma Announces Commencement of Public Offering of Ordinary Shares and Pre-Funded Warrants
5:07pm
; or Guggenheim Securities, LLC, Attention: Equity Syndicate Department, 330 Madison Avenue, New York, NY 10017, telephone: (212) 518-5548, email
424B5
URGN
UroGen Pharma Ltd
18 Jun 24
Prospectus supplement for primary offering
5:05pm
by a Shareholder of a Passive Foreign Investment Company or Qualified Electing Fund) containing such information as the U.S. Treasury Department may require
424B5
URGN
UroGen Pharma Ltd
17 Jun 24
Prospectus supplement for primary offering
4:19pm
as the U.S. Treasury Department may require. The failure to file IRS Form 8621 could result in the imposition of penalties and the extension of the statute
8-K
EX-99.1
t2dz48wb0t1dbb in
13 Jun 24
Regulation FD Disclosure
10:51am
8-K
EX-10.1
3pk9zi78q
27 Jul 23
UroGen Announces $120 Million Private Placement of Ordinary Shares
9:57am
424B5
ypqyoxc1v6dwtfi8qv2m
1 Dec 22
Prospectus supplement for primary offering
4:05pm